Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdfAccessed April 7, 2015
   Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• SantusPCentanniSVergaMDi MarcoFMateraMGCazzolaMComparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflationRespir Med20061001277128116337781
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and Tiotropium compared with Tiotropium alone for treatment of COPDCOPD200961172519229704
   PubMedGoogle Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• CazzolaMCentanniSSantusPThe functional impact of adding salmeterol and tiotropium in patients with stable COPDRespir Med2004981214122115588043
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• AaronSDVandehmheenKLFergussonDfor Canadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBfor TORCH investigatorsSalmeterol and flucticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• Spiriva^® 18 microgram inhalation powder, hard capsule [UK summary of product characteristics, online]Berkshire, UKBoehringer Ingelheim International GmbH Available from: http://www.medicines.org.uk/EMC/medicine/10039/SPC/Spiriva+18+microgram+inhalation+powder%2c+hard+capsuleAccessed April 7, 2015
   Google Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar
• Striverdi^® Respimat^® (olodaterol) inhalation spray for oral inhalation [US prescribing information]Berkshire, UKBoehringer Ingelheim International GmbH2014 Available from: http://www.boehringeringelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/StriverdiPMEN.pdfAccessed April 7, 2015
   Google Scholar
• GmbHBoehringer Ingelheim announces U.S. filing for the fixed-dose combination tiotropium plus olodaterol for patients with COPD [press release];8192014 Available from: http://us.boehringeringelheim.com/news_events/press_releases/press_release_archive/2014/08-19-14-boehringer-ingelheim-us-filing-fixed-dose-combination-tiotropium-plus-olodaterol-patients-copd.htmlAccessed April 7, 2015
   Google Scholar
• BoehringerIngelheimPharmaceuticals, IncFDA Approves Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for COPD [press release]Boehringer Ingelheim Pharmaceuticals, Inc.20155 Available from: http://www.drugs.com/newdrugs/fda-approves-stiolto-respimat-tiotropium-bromide-olodaterol-inhalation-copd-4216.htmlAccessed July 10, 2015
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, IncSTIOLTO™ RESPIMAT^® Now Available in the United States for the Treatment of COPD [press release]Boehringer Ingelheim Pharmaceuticals, Inc2015630 Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/6-30-2015-stiolto-respimat-available-united-states-treatment-copd.htmlAccessed July 10, 2015
   Google Scholar
• KeatingGMTiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary diseaseDrugs20127227330022217233
   PubMed Web of Science ®Google Scholar
• SantusPBuccellatiCCentanniSBronchodilators modulate inflammation in chronic obstructive pulmonary disease subjectsPharmacol Res20126634334822659487
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSTiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax2006611085486216844726
   PubMed Web of Science ®Google Scholar
• YohannesAMConnollyMJHananiaNATen years of tiotropium: clinical impact and patient perspectivesInt J Chron Obstruct Pulmon Dis2013811712523515335
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonistexerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• Van NoordJAKorduckiLHamiltonAKokerPFour weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract]Am J Respir Crit Care Med2009179A6183
   Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION of STIOLTO Available from: http://bidocs.boehringeringelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Stiolto+Respimat/stiolto.pdfAccessed July 10, 2015
   Google Scholar
• VogelmeierCHedererBGlaabTfor POET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSfor UPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• PedoneCIncalziRATiotropium in chronic obstructive pulmonary diseaseN Engl J Med200936018519129533
   PubMed Web of Science ®Google Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomised studiesInt J COPD20105197208
   Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAfor INSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J20042383284015218994
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• BriggsDDJrCovelliHLapidusRBhattycharyaSKestenSCassinoCImproved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPDPulm Pharmacol Ther200518639740416179215
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJfor INHANCE Study InvestigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indaceterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCfor INTENSITY study investigatorsBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• ChongJKarnerCPoolePTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00915722972134
   PubMed Web of Science ®Google Scholar
• Van NoordJACornelissenPJAumannJLPlatzJMuellerAFogartyCThe efficacy of tiotropium administered via Respimat® Soft Mist Inhaler or HandiHaler® in COPD patientsRespir Med2009103222919022642
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• FergusonGFeldmanGHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• LangePAumannJ-LDeromEThe 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studies [abstract]Eur Respir J201342Suppl 57982s4635
   Google Scholar
• IchinoseMTakizawaAIzumotoTFukuchiYEfficacy of 4 weeks’ once-daily treatment with olodaterol (BI 1744), a novel long-acting β2-agonist, in Japanese patients with COPD [abstract]Am J Respir Crit Care Med2012185A2931
   Google Scholar
• MaltaisFKirstenAHamiltonADe SousaDWangFDecramerMEvaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studiesAbstract 748A presented at: CHESTChicago, IL, USAOctober 26–31, 2013
   Google Scholar
• McGarveyLNiewoehnerDMagderSOne-year safety of olodaterol once daily via Respimat in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis [abstract]COPD Epub 2182015
   Google Scholar
• MuruganandanSJayaramLProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPDInt J Chron Obstruct Pulmon Dis2015101179118926124657
   PubMed Web of Science ®Google Scholar
• BouyssouTSchnappACasarosaPPieperMPAddition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract A4445]Am J Respir Crit Care Med2010181A4445
   Google Scholar
• MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium ioolodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]Eur Respir J2010361014s
   Google Scholar
• AalbersRMaleki-YazdiMRHamiltonADose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPDEur Respir J201240525s526s
   Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J20154596997925573406
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimCharacterization of 24-hour lung function profiles of inhaled tiotropium plus olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease Available from: https://www.clinicaltrials.gov/ct2/show/NCT1559116?term=NCT1559116&rank=1Accessed April 5, 2015
   Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• MaltaisFGáldizIturriJBKirstenAP250 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPDThorax201469A186A187
   Web of Science ®Google Scholar
• Characterization of lung function profile of inhaled tiotropium plus olodaterol fixed dose combination compared to fluticasone propionate + salmeterol fixed dose combination in COPD patients ClinicalTrials.gov Identifier: NCT19697212013 Available from: https://clinicaltrials.gov/ct2/show/NCT1969721Accessed July 20, 2015
   Google Scholar
• ARCAPTA™ NEOHALER™ (indacaterol inhalation powder) [US prescribing information]Stein, SwitzerlandNovartis Pharma Stein AG2012 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/arcapta.pdfAccessed April 7, 2015
   Google Scholar
• Stiolto respimat (tiotropium bromide and olodaterol) [prescribing information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals62015
   Google Scholar
• TashkinDFergusonGCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• KhachikianDOlodaterol (Striverdi Respimat) National Drug Monograph32015 Available from: http://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Olodaterol_Monograph.pdfAccessed April 20, 2015
   Google Scholar
• Boehringer IngelheimComparing the efficacy of tiotropium plus olodaterol (5/5 μg) fixed dose combination (FDC) over tiotropium 5 μg in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease Available from: https://www.clinicaltrials.gov/ct2/show/NCT2296138?term=NCT2296138&rank=1. NLM identifier: NCT2296138Accessed April 20, 2015
   Google Scholar